Davita Inc vs Hinge Health Inc. Class A Common Stock — how do they compare? Davita Inc trades at $180.7 (market cap $11.53B), while Hinge Health Inc. Class A Common Stock trades at $103.99 (market cap $8.47B). The key difference: Davita Inc is the larger of the two by market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| DVA | HNGE | |
|---|---|---|
Market Cap | $11.53B | $8.47B |
Volume | 444,368 | 1,624,526 |
Sector | Health | Health |
52-Week High | $240.96 | $105.14 |
52-Week Low | $103.87 | $31.17 |
Typical Hold Time | 114 Days | 0 Days |
Enterprise Value | $24.25B | $8.09B |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $182.08, up 0.17% with a bullish technical outlook. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026), revenue growth from $11.6B to $13.6B (2022-2025), and attractive valuation at P/E 15.43. Recent partnership expansion with Humana for value-based kidney care and institutional buying by BlackRock ($547.5M) support positive momentum. Operating cash flow remains robust at $1.89B (2025), though net cash flow turned negative due to debt repayments.
Outlook: DVA offers upside to consensus target ($235.67) with 29% potential, backed by earnings growth and strategic partnerships. Risks include high debt (debt-to-asset 65.55%), regulatory pressures, and margin volatility. Analyst consensus leans Hold (52.17%) amid balanced growth prospects and financial leverage concerns.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →